Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours
← catalyst calendarNCT07446855 · readout in 1,318 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
180estimated
Sites
19
Countries
Australia, Japan, South Korea +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-17 | actual | When the study began enrolling |
| Primary completion | 2030-03-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-03-29 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Tumours
Interventions
- Drug: AZD4956
- Drug: Saruparib
Primary outcomes
what the primary-completion date above is the date OFParts A and B: Number of participants with adverse events (AEs) and serious adverse events (SAEs)
measured From Screening (Day -28) to follow-up (up to 3.5 years)
Part B: Progression free survival (PFS)
measured Up to 3.5 years
Part A - Number of participants with dose-limiting toxicities (DLTs)
measured Up to 28 days
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed